Shares of Xencor Inc (NASDAQ:XNCR) have been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $34.25.
Several research firms recently issued reports on XNCR. BidaskClub raised Xencor from a “buy” rating to a “strong-buy” rating in a research note on Friday. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $37.00 price objective on shares of Xencor in a research note on Thursday, March 1st. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th.
Xencor (NASDAQ:XNCR) traded up $0.71 during trading hours on Wednesday, reaching $32.72. The company had a trading volume of 225,628 shares, compared to its average volume of 247,439. The company has a market capitalization of $1,504.79, a price-to-earnings ratio of -31.46 and a beta of 1.50. Xencor has a 12 month low of $18.55 and a 12 month high of $33.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its position in Xencor by 6.0% during the second quarter. The Manufacturers Life Insurance Company now owns 29,771 shares of the biopharmaceutical company’s stock valued at $629,000 after purchasing an additional 1,673 shares in the last quarter. Nationwide Fund Advisors raised its position in Xencor by 4.5% during the third quarter. Nationwide Fund Advisors now owns 62,180 shares of the biopharmaceutical company’s stock valued at $1,425,000 after purchasing an additional 2,676 shares in the last quarter. Vident Investment Advisory LLC raised its position in Xencor by 5.9% during the fourth quarter. Vident Investment Advisory LLC now owns 59,426 shares of the biopharmaceutical company’s stock valued at $1,303,000 after purchasing an additional 3,289 shares in the last quarter. Swiss National Bank increased its holdings in shares of Xencor by 5.2% in the third quarter. Swiss National Bank now owns 66,400 shares of the biopharmaceutical company’s stock worth $1,522,000 after buying an additional 3,300 shares during the period. Finally, Voya Investment Management LLC increased its holdings in shares of Xencor by 25.4% in the second quarter. Voya Investment Management LLC now owns 16,793 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 3,405 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.
WARNING: “Xencor Inc (XNCR) Receives $34.25 Average Price Target from Brokerages” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3254084/xencor-inc-xncr-receives-34-25-average-price-target-from-brokerages.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.